| Diana N Striffler, APRN | |
|
47 Town St, Norwich, CT 06360-2315 | |
| (860) 892-7042 | |
| Not Available |
| Full Name | Diana N Striffler |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 12 Years |
| Location | 47 Town St, Norwich, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174861702 | NPI | - | NPPES |
| 008043653 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 5276 (Connecticut) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Starling Physicians, Pllc | 7517863749 | 204 |
News Archive
Sciele Pharma, Inc. today announced that Plethora Solutions Holdings PLC has completed its European Phase III study of PSD502 for the treatment of premature ejaculation (PE) in Europe. The study was initiated in December 2007 and these results from the blinded study are expected in the fourth quarter of 2008.
Various states have passed or are considering bills to tighten abortion regulations.
Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease and reported on their application of these criteria in clinical trials during the recently completed National Hemophilia Foundation Annual Meeting.
Non-small cell lung cancer (NSCLC) survivors who never smoked or who are former smokers at the time of diagnosis have a lower risk of developing secondary primary lung cancers (SPLC) compared to those who are current smokers, suggesting that increased tobacco exposure is associated with a higher risk of SPLC, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.
Two Ottawa researchers are taking innovative approaches to improving virus-based cancer therapy with new funding from the Canadian Cancer Society.
› Verified 4 days ago
| Entity Name | Prohealth Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720194053 PECOS PAC ID: 1355246950 Enrollment ID: O20031205000602 |
News Archive
Sciele Pharma, Inc. today announced that Plethora Solutions Holdings PLC has completed its European Phase III study of PSD502 for the treatment of premature ejaculation (PE) in Europe. The study was initiated in December 2007 and these results from the blinded study are expected in the fourth quarter of 2008.
Various states have passed or are considering bills to tighten abortion regulations.
Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease and reported on their application of these criteria in clinical trials during the recently completed National Hemophilia Foundation Annual Meeting.
Non-small cell lung cancer (NSCLC) survivors who never smoked or who are former smokers at the time of diagnosis have a lower risk of developing secondary primary lung cancers (SPLC) compared to those who are current smokers, suggesting that increased tobacco exposure is associated with a higher risk of SPLC, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.
Two Ottawa researchers are taking innovative approaches to improving virus-based cancer therapy with new funding from the Canadian Cancer Society.
› Verified 4 days ago
| Entity Name | Starling Physicians, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467537290 PECOS PAC ID: 7517863749 Enrollment ID: O20031209000877 |
News Archive
Sciele Pharma, Inc. today announced that Plethora Solutions Holdings PLC has completed its European Phase III study of PSD502 for the treatment of premature ejaculation (PE) in Europe. The study was initiated in December 2007 and these results from the blinded study are expected in the fourth quarter of 2008.
Various states have passed or are considering bills to tighten abortion regulations.
Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease and reported on their application of these criteria in clinical trials during the recently completed National Hemophilia Foundation Annual Meeting.
Non-small cell lung cancer (NSCLC) survivors who never smoked or who are former smokers at the time of diagnosis have a lower risk of developing secondary primary lung cancers (SPLC) compared to those who are current smokers, suggesting that increased tobacco exposure is associated with a higher risk of SPLC, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.
Two Ottawa researchers are taking innovative approaches to improving virus-based cancer therapy with new funding from the Canadian Cancer Society.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Diana N Striffler, APRN 47 Town St, Norwich, CT 06360-2315 Ph: (860) 892-7042 | Diana N Striffler, APRN 47 Town St, Norwich, CT 06360-2315 Ph: (860) 892-7042 |
News Archive
Sciele Pharma, Inc. today announced that Plethora Solutions Holdings PLC has completed its European Phase III study of PSD502 for the treatment of premature ejaculation (PE) in Europe. The study was initiated in December 2007 and these results from the blinded study are expected in the fourth quarter of 2008.
Various states have passed or are considering bills to tighten abortion regulations.
Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease and reported on their application of these criteria in clinical trials during the recently completed National Hemophilia Foundation Annual Meeting.
Non-small cell lung cancer (NSCLC) survivors who never smoked or who are former smokers at the time of diagnosis have a lower risk of developing secondary primary lung cancers (SPLC) compared to those who are current smokers, suggesting that increased tobacco exposure is associated with a higher risk of SPLC, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.
Two Ottawa researchers are taking innovative approaches to improving virus-based cancer therapy with new funding from the Canadian Cancer Society.
› Verified 4 days ago
Mafe Duyan Rato, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 624 W West Main St, St 140, Norwich, CT 06360 Phone: 860-200-8098 | |
Meagan Gates, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 372 W Main St, Norwich, CT 06360 Phone: 860-887-5970 | |
Mrs. Polina Verbitsky-havasov, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 42 Town St Ste 300, Norwich, CT 06360 Phone: 860-886-0567 Fax: 860-886-0656 | |
Sarah Jean Robertson, MSN, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 606 W Main St, Norwich, CT 06360 Phone: 860-889-1400 | |
Ms. Lindsay Anne Bizzaro, NNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 326 Washington St, Norwich, CT 06360 Phone: 614-378-1802 | |
Jessica Banning, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1 Lathrop Ave, Norwich, CT 06360 Phone: 860-204-0883 | |
Olubunmi Olugbile, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 326 Washington St, Norwich, CT 06360 Phone: 860-889-8331 |